Vall

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
International SOS, Disease, Partnership, International, Patient, Hospitality, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
Disease, Partnership, Patient, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers - those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
International SOS, Disease, Partnership, International, Patient, Hospitality, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
Disease, Partnership, Patient, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers - those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

Retrieved on: 
Friday, January 19, 2024
Vall d'Hebron University Hospital, Teaching hospital, Borderline personality disorder, Yale school, BPD, Yale School of Medicine, MD, Vall, Genomics, Webcast, Doctor of Philosophy, KOL, Phase

To register for the event, click here .

Key Points: 
  • To register for the event, click here .
  • The event will feature a brief review of the topline results of the Phase IIb PORTICO study, then a discussion with:
    KOL Marc Ferrer, MD, PhD (Vall d'Hebron University Hospital), PORTICO E.U.
  • KOL Sarah Fineberg, MD, PhD (Yale School of Medicine), a Psychiatrist not involved with PORTICO to provide an independent clinician’s perspective on the potential clinical and real-world implications for the results.
  • A replay of the webcast will be available on the company’s website after the event.

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

Retrieved on: 
Wednesday, November 29, 2023
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Acquisition, Pompeu Fabra University, Vall, Regulatory affairs, Therapy, Osteoarthritis, ALK5, University, Patient, Idiopathic pulmonary fibrosis, FDA, SAB, Idiopathic disease, JIA, Coronavirus Scientific Advisory Board, Novartis, MD, Cancer, MET, Drug development, CMC, SVP, Doctor of Philosophy, MD–PhD, Scripps Research, Genentech, Amgen, Management, Pharmaceutical industry, Origo, Immunology

Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.

Key Points: 
  • Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.
  • As part of the next growth phase of the company, Paolo Michieli, PhD, (Founder and formerly Chief Scientific Officer) and Torsten Dreier, PhD, (previously Chief Development Officer) will continue at Agomab as senior advisors and members of the Scientific Advisory Board (SAB).
  • “Angelika’s extensive experience and deep knowledge as a senior drug developer will be of great value to the Board and our company.
  • Andrea Sáez was COO/CSO at Origo Biopharma where she led the development of ALK5 inhibitor programs through preclinical and early clinical stages.

Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Retrieved on: 
Thursday, November 16, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, USC, Assistant, Associate, Safety, Vall, Head, Clinical research, Teaching hospital, Multimedia, CLDN1, Pharmacokinetics, Neoplasm, University, Cancer, University of Southern California, Pharmaceutical industry, Medicine, MD

The patient is enrolled under the Phase I program, led by Anthony El-Khoueiry, MD, Associate Director of Clinical Research, at University of Southern California (USC) Norris Comprehensive Cancer Center, part of Keck Medicine of USC.

Key Points: 
  • The patient is enrolled under the Phase I program, led by Anthony El-Khoueiry, MD, Associate Director of Clinical Research, at University of Southern California (USC) Norris Comprehensive Cancer Center, part of Keck Medicine of USC.
  • View the full release here: https://www.businesswire.com/news/home/20231116577905/en/
    The open-label, multi-center, Phase 1/2 clinical trial ( NCT06054477 ) will investigate ALE.C04 as a single agent and in combination with pembrolizumab (anti-PD-1 antibody) in 220 adults with recurrent or metastatic (R/M) head and neck squamous cell carcinoma.
  • “ALE.C04 is a first-in-class antibody for treating cancer and has shown much potential in preclinical models,” said Luigi Manenti, MD, Chief Medical Officer of Alentis.
  • I am looking forward to the data and to developing ALE.C04 for other CLDN1+ tumors including colorectal cancer.”

CARsgen Announces Formation of its Clinical Advisory Board

Retrieved on: 
Monday, November 20, 2023
Dexamethasone, Experiment, Teaching hospital, Patient, Strategic planning, Bortezomib, Vall d'Hebron University Hospital, Cancer, Ernest Beutler, TCO, Doctor of Philosophy, Knowledge, Axicabtagene ciloleucel, University of Miami, Multiple myeloma, Douglas E. Lynch, R.J. Corman Railroad Group, University, ESMO, Harvard Medical School, Regorafenib, Biomarker, Principal, Translation, Vall, MD Anderson Cancer Center, Lenalidomide, Therapy, National Cancer Institute, Dana–Farber Cancer Institute, MGUS, Publication, Drug development, NCI-designated Cancer Center, The Lancet, Research, Lymphoid leukemia, NCI, CD19, MRD, FDA, MD, Survival, Lymphoma, Pharmaceutical industry, Daratumumab, Medicine, Immunotherapy

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.

Key Points: 
  • SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.
  • This highly regarded panel of experts will provide invaluable guidance and insights for the global clinical development of company's innovative product candidates.
  • "As we embark on this exciting journey to advance our differentiated CAR T-cell therapies, I am delighted to welcome our esteemed Clinical Advisory Board members.
  • The formation of this Clinical Advisory Board marks a significant step forward for CARsgen as it continues to pioneer CAR T-cell therapies with the potential to transform cancer treatment.

Perfuze® Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System

Retrieved on: 
Thursday, November 2, 2023
General Health, Medical Devices, Health, Clinical Trials, Cardiology, Principal investigator, MARRS, FDA, Stony Brook University Hospital, Trial of the century, Reperfusion, Thrombectomy, Clinical trial, U.S. FDA, Safety, Vall, European, Patient, Diagnosis, Death, Hospital, CE marking, Pharmaceutical industry, Stroke

Perfuze , a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Revascularization in Stroke) clinical study.

Key Points: 
  • Perfuze , a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Revascularization in Stroke) clinical study.
  • MARRS is a multi-center trial to evaluate the performance of the Millipede System.
  • “I am delighted to begin enrollment in the MARRS pivotal study” said Dr David Fiorella, Director of the Stony Brook Cerebrovascular Center, NY.
  • The study will evaluate the performance and safety of the Millipede System in patients with acute ischemic stroke.

Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference

Retrieved on: 
Monday, October 23, 2023
Professional Services, Oncology, Health, Venture Capital, Pharmaceutical, Biotechnology, FDA, Breast, AACR, IND, Optimism, Ovarian cancer, Food, JD, Hope, HER2, Progesterone, Conference, Pharma, Doctor of Philosophy, Carcinoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Breast cancer, Multimedia, TNBC, Neoplasm, Luminal, Woman, Vall, Circle, Patient, Pharmaceutical industry, Medical imaging

This significant development was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Key Points: 
  • This significant development was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
  • Most notably, multiple triple-negative breast cancer (TNBC) cell lines and luminal B breast cancer cell lines displayed sensitivity to Cyclin A/B inhibition.
  • These findings were instrumental in selecting TNBC and luminal breast cancer patient-derived tumor models for subsequent in vivo efficacy studies.
  • Triple negative breast cancer, which accounts for 10-20% of all breast cancer cases, is an aggressive and challenging subtype of breast cancer, associated with poor prognosis and high risk of relapse1.